Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation
Open Access
- 10 June 2025
- journal article
- case report
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-4
Abstract
Chemoradiotherapy (CRT) with consolidative immunotherapy(IO) remains the standard care for unresectable stage III NSCLC, yet survival remains suboptimal in molecular subgroups. Emerging targeted therapies offer the potential for converting unresectable cases to resectable status. We present a 54-year-old female with stage IIIB (T1cN3M0) ERBB2 exon 20-mutated lung adenocarcinoma (PD-L1 50%) and supraclavicular metastasis. After three cycles of ERBB2-targeted antibody-drug conjugate combined with programmed death-1 (PD-1) inhibitor, transient Grade 1 interstitial lung disease resolved with steroids. Serial imaging revealed 58% tumor regression, enabling successful R0 resection via VATS lobectomy with lymphadenectomy. Histopathological analysis confirmed complete pathological response in primary and nodal lesions, corroborated by undetectable postoperative minimal residual disease. The patient remained recurrence-free at a 9-month follow-up. This induction targeted-IO strategy enabled surgical conversion in ERBB2-mutant NSCLC with durable remission and acceptable toxicity, warranting investigation in molecular subgroups with limited CRT-IO benefit.Keywords
This publication has 15 references indexed in Scilit:
- Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)Signal Transduction and Targeted Therapy, 2024
- Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trialCancer Cell, 2024
- Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancerTrends in Cancer, 2024
- Perioperative Nivolumab in Resectable Lung CancerNew England Journal of Medicine, 2024
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung CancerNew England Journal of Medicine, 2023
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerNew England Journal of Medicine, 2022
- Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2022
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2021
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017